Biotech group Neuren Pharmaceuticals has reported a 14% uptick in quarterly US sales of its Retts syndrome treatment Daybue.

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

The ASX200 has been trading in the red leading into the close. Industrials, Health Care, and Energy were the poorest performing sectors in afternoon trade. On the green side of things, Real Estate, ...

Dual-listed across the Nasdaq composite and the ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as sales of its flagship drug DAYBUE jump +14% on Q2 2024. Listen ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

Aug 2025 - Acadia Pharmaceuticals reports a 14% increase in DAYBUE™ net sales, boosting Neuren's royalty income.

Rett syndrome hits hard and early, but with Neuren’s Daybue and Neurotech’s cannabis-based NTI164 building steam, the fight ...